ProCE Banner Activity

Atezolizumab: A New Treatment Option for Progressive Metastatic NSCLC

Clinical Thought
There is now a third checkpoint inhibitor approved for metastatic NSCLC. Melissa L. Johnson, MD, discusses the latest clinical data from ESMO 2016 that led to the FDA approval of atezolizumab for advanced NSCLC that has progressed on previous platinum-based chemotherapy.

Released: December 20, 2016

Expiration: December 19, 2017

No longer available for credit.

Share

Faculty

Melissa L. Johnson

Melissa L. Johnson, MD

Assistant Professor
Division of Hematology/Oncology
Robert H. Lurie Comprehensive Cancer Center 
Northwestern University
Assistant Attending
Divison of Hematology/Oncology
Northwestern Memorial Hospital
Chicago, Illinois

Provided by

Jointly provided by Postgraduate Institute for Medicine and Clinical Care Options, LLC
ProCE Banner

Supporters

This activity is supported by educational grants from

AbbVie

Celgene

Genentech Roche Virology

Lilly

Merck Oncology

Novartis Pharmaceuticals Corporation

Faculty Disclosure

Primary Author

Melissa L. Johnson, MD

Assistant Professor
Division of Hematology/Oncology
Robert H. Lurie Comprehensive Cancer Center 
Northwestern University
Assistant Attending
Divison of Hematology/Oncology
Northwestern Memorial Hospital
Chicago, Illinois

Melissa L. Johnson, MD, has disclosed that she has received funds for research support from Array, AstraZeneca, BerGenBio, EMD Serono, Genentech, Genmab, Janssen, Kadmon, Lilly, Novartis, OncoMed, Pfizer, Regeneron, and Stemcentrx and that her spouse has received government lobbyist retaining fees from Astellas and Otsuka.